ANNEXIN XI

Abstract: Provided are DNA sequences, recombinant DNA molecules and hosts transformed with them which produce annexin XI polypeptides and methods of making and using these products. Also provided are antibodies generated against all or an immunogenic portion of annexin XI and methods for using these antibodies.

Description: ANNEXIN XI Background of the Invention The invention relates to DNA sequences, recombinant DNA molecules and processes for producing annexin XI as well as methods for using annexin XI. The annexins (or lipocortins) are a family of more than ten structurally related proteins. Annexins have been identified in a variety of eukaryotes from slime molds to mammals and higher plants, and the cDNAs encoding eight distinct mammalian annexins have been sequenced. All annexins have a conserved core domain and a highly variable amino terminal domain. The core domain consists of a 60-70 amino acid motif which is repeated four times in the smaller annexins (30-50kD) and eight times in the larger annexins (~70kD) . The amino acid sequence of this core domain is 45 to 65% conserved between various annexins. For a given annexin the entire amino acid sequence is roughly 90% conserved between different mammalian species. Annexins bind phospholipids and Ca 2+ and associate with membrane preparations in a Ca 2+ -dependent manner. Analysis of proteolytic fragments of several annexins indicates that the phospholipid and Ca 2+ binding sites lie within the conserved core domain. Many, if not all, annexins inhibit phospholipase A 2 (P A 2 ) , an enzyme which releases fatty acids (e.g., arachidonic acid) esterified at the S N 2 position of membrane phospholipids. It is thought that annexins inhibit PLA 2 activity by binding to phospholipids and blocking their interaction with PLA 2 . Arachidonic acid is a precursor in the synthesis of compounds, such as prostaglandins and leukotrienes, that are involved in inflammation. The lysophospholipids and their derivatives, such as platelet activating factor (PAF) , may also promote inflammatory responses. Accordingly, it has been suggested that annexins may be useful for the treatment of inflammation. Purified annexins have been shown to have anti-inflammatory activity in vivo (Parente et al., JSur. J. Pharmacol . 99:233, 1984). Unlike many non-steroidal anti- inflammatory compounds, annexins have the potential to block an earlier step in the eicosanoid-generated production of inflammatory substances, via the cyclooxygenase pathway or the lipoxygenase pathway as well as via lysophospholipids and related mediators. It has been suggested that annexins may have anti¬ coagulant activity. Factor X a -catalyzed activation of prothrombin, an important step in coagulation, is accelerated by protein cofactor V a and negatively charged phospholipids. Thus, annexins, by virtue of their ability to bind phospholipids, might inhibit prothrombin activation. Reutelingsperger et al. (Eur. J. Biochem. 173:171, 1988) describe an inhibitor of blood coagulation, VAC (annexin V) , isolated from the intima of bovine aorta. This protein binds phospholipids in a Ca 2+ - dependent manner. In a purified coagulation system this protein inhibited activation of prothrombin by factor X a . Odenwald et al. (Biochem. and Biophys . Res . Comm . 112:147, 1983) disclose a 56 kD annexin-like protein (synexin II) isolated from bovine adrenal medulla and liver. Odenwald et al. report that synexin-II enhances Ca 2+ -induced aggregation of chromaffin granule membranes and that this activity is protease resistant. Towle et al. (Transactions of the 36th Annual Meeting of the Orthopaedic Research Society, February, 1990) report the use of antibodies raised against an anti-collagenase activator protein (stromelysin) to identify a clone in an interleukin-1 stimulated bovine chondrocyte cDNA expression library. Towle et al. report that partial sequence analysis of this clone predicts that it encodes a protein similar to lipocortins (annexins) I and II as well as PP4X (annexin IV) . Northern analysis indicated that the steady state level of RNA capable of hybridizing to this cDNA clone increases four-fold upon exposure of chondrocytes to interleukin-1. Towle et al. (Orthopaedic Trans . 14:343, 1990) describe a clone cp4x, isolated from a bovine cartilage cDNA library. A cartilage protein, immunologically cross-reactive with the fusion protein encoded by cp4X, co-purified (during initial purification steps) with other annexins. The clone encodes a protein that co- purifies with annexins and is homologous to pp4x (annexin IV). Towle et al. report that the steady state level of mRNA encoding cp4x is lower in interleukin-1 stimulated bovine chondrocytes than in non-stimulated chondrocytes. Wallner et al. (U.S. 4,950,646) report the isolation of a cDNA encoding a 363 amino acid human lipocortin. E. coli or yeast transformed with a plasmid capable of expressing the lipocortin cDNA produce a 37 kD protein that is not produced in untransformed cells. Wallner et al. also report the isolation of a partial cDNA clone of a second lipocortin, N-lipocortin, which is homologous to their originally isolated lipocortin. Wallner et al. (European Patent Application 0 330 396) report the isolation of cDNAs encoding human lipocortins III and V and the purification of bovine lipocortins IV and VI. Huang et al. (J. Biol . Chem . 262:7639, 1989) report the identification of several proteolytic fragments of human lipocortin (annexin) I that are capable of inhibiting phospholipase A 2 . Huang et al. suggest that a region of lipocortin I from amino acids 83-346 may be important for lipocortin activity. Summary of the Invention In general, the invention features an isolated nucleic acid encoding an annexin XI polypeptide, the polypeptide having at least 70%, preferably at least 80%, or more preferably at least 90% homology to the amino acid sequence of bovine annexin XI type I (SEQ ID NO:2) or bovine annexin XI type II (SEQ ID NO:4) . In preferred embodiments, the nucleic acid encodes a human annexin XI polypeptide. In a related aspect, the invention features a nucleic acid having at least 70% homology to bovine annexin XI type I cDNA (SEQ ID N0:1) or bovine annexin XI type II cDNA (SEQ ID NO:3). In another aspect, the invention features a plasmid which includes a nucleic acid encoding an annexin XI polypeptide, the polypeptide having at least 70% homology to the amino acid sequence of bovine annexin XI type I (SEQ ID NO:2) or bovine annexin XI type II (SEQ ID NO:4) . Preferably, the plasmid includes an expression control sequence capable of directing expression of the annexin XI polypeptide. In a related aspect, the invention features a cell which includes a nucleic acid encoding an annexin XI polypeptide, the polypeptide having at least 70% homology to the amino acid sequence of bovine annexin XI type I (SEQ ID NO:2) or bovine annexin XI type II (SEQ ID NO:4) . In preferred embodiments, the cell is a prokaryotic cell, the cell is a eukaryotic cell, and the cell is a mammalian cell. In another aspect, the invention features annexin XI produced by expression of a nucleic acid encoding an annexin XI polypeptide, the polypeptide having at least 70% homology to the amino acid sequence of bovine annexin XI type I (SEQ ID NO:2) or bovine annexin XI type II (SEQ ID NO:4) . In a related aspect, the invention features annexin XI produced by a cell which includes a nucleic acid encoding an annexin XI polypeptide, the polypeptide having at least 70% homology to the amino acid sequence of bovine annexin XI type I (SEQ ID NO:2) or bovine annexin XI type II (SEQ ID NO.4) . In another aspect, the invention features an antibody generated against all or an immunogenic portion of annexin XI, which antibody is capable of specifically forming an immune complex with annexin XI. Antibodies which specifically recognize either annexin XI type I or annexin XI type II as well as antibodies which recognize an epitope shared by type I and type II annexin XI are featured in the instant invention. In another aspect, the invention features a substantially pure annexin XI polypeptide. In preferred embodiments, the polypeptide has at least 70%, preferably at least 80%, more preferably at least 90%, homology to the amino acid sequence of bovine annexin XI type I (SEQ ID NO: 2) or bovine annexin XI type II (SEQ ID NO: 4) . In another preferred embodiment, the polypeptide is a human annexin XI polypeptide. In yet another preferred embodiment, the polypeptide has the sequence of bovine annexin XI type I (SEQ ID NO: 2) or bovine annexin XI type II (SEQ ID N0:4). In a related aspect, the invention features a therapeutic composition which includes, in a pharmaceutically-acceptable carrier, a substantially pure annexin XI polypeptide or a coagulation inhibiting- fragment thereof. In another related aspect, the invention includes a therapeutic composition which includes,. in a pharmaceutically-acceptable carrier, a substantially pure annexin XI polypeptide, or an anti-inflammatory fragment thereof. In another related aspect, the invention includes a therapeutic composition which includes, in a pharmaceutically-acceptable carrier, a substantially pure annexin XI polypeptide, or a phospholipase A 2 -inhibiting fragment thereof. The invention also features a method of detecting annexin XI in a sample of biological fluid; the method includes the steps of: (a) contacting the sample of biological fluid with an antibody generated against all or an immunogenic portion of annexin XI, which antibody is capable of specifically forming an immune complex with annexin XI; and (b) detecting immune complexes formed in step (a) , formation of the immune complexes being an indication of the presence of the annexin XI. In another aspect the invention includes a method of detecting an antibody reactive with annexin XI in a sample of biological fluid; the method includes the steps of: (a) contacting the sample of biological fluid with a substantially pure annexin XI polypeptide or an immunogenic fragment thereof; and (b) detecting immune complexes formed in step (a) , formation of the immune complexes being an indication of the presence of the antibody reactive with annexin XI. Finally, the invention features a method of reducing inflammation in a mammal involving administering to the mammal a therapeutically-effective amount of an annexin XI polypeptide or an anti-inflammatory fragment thereof in a pharmaceutically-acceptable carrier; and a method of reducing coagulation in a mammal involving administering to the mammal a therapeutically-effective amount of an annexin XI polypeptide or a coagulation- inhibiting fragment thereof in a pharmaceutically- acceptable carrier. By "isolated" is meant that the nucleic acid is largely free of the coding sequences of those genes that, in the naturally occurring genome of the organism from which the nucleic acid is derived, directly flank the nucleic acid. Isolated nucleic acid may be genomic DNA, cDNA, chemically synthesized nucleic acid, enzymatically synthesized nucleic acid, or recombinant nucleic acid. The term includes chemically and enzymatically synthesized nucleic acid produced using a recombinant nucleic acid as a template. By "plasmid" is meant an extrachromosal DNA molecule which includes sequences that permit replication within a particular host cell. By "expression control sequence" is meant a nucleotide sequence which includes recognition sequences for factors that control expression of a protein coding sequence to which it is operably linked. Accordingly, an expression control sequence generally includes sequences for controlling both transcription and translation, for example, promoters, ribosome binding sites, repressor binding sites, and activator binding sites. "Homology" for amino acid sequences refers to the similarity between two or more amino acid sequences. The percent homology of two given proteins is usually determined using sequence analysis software (e.g. , the Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin, Madison, WI) . Such software determines the homology of two amino acid sequences that have been aligned so as to maximize homology. Homology values are assigned to exact matches as well as certain types of substitutions. By "substantially pure" is meant a polypeptide or protein which has been separated from components (e.g., other proteins) with which it is normally found. Typically, a protein or polypeptide of interest is substantially pure when at least 75% (preferably 85%) of the polypeptide in a sample is the protein or polypeptide of interest. By the term "capable of forming a specific immune complex" is meant an antibody does not substantially bind other molecules. Besides substantially full-length annexin XI, the present invention provides biologically active fragments of annexin XI. As used herein, the term "fragment", as applied to annexin XI, will ordinarily be about 5 contiguous amino acids and will preferably be at least 10 or at least 20 contiguous amino acids. Such fragments may be included in larger polypeptides provided that the non-annexin XI amino acid sequences do not destroy biological activity. Multiple annexin XI fragments may be combined in a single polypeptide in any biologically active arrangement. By "coagulation-inhibiting fragment" is meant a fragment of annexin XI which inhibits coagulation in a standard coagulation assay. Reutelingsperger et al. (Eur. J. Biochem. 151:625, 1985, hereby incorporated by reference) describe a modified prothrombin time test which is suitable for determining the coagulation- inhibiting activity of annexin XI and fragments thereof. Preferred fragments, when present at a concentration of 1 to 100 μK r at least double the clotting time in this assay. By "annexin XI" is meant all alternatively spliced forms of annexin XI encoded by the same genomic locus. By an "anti-inflammatory fragment" is meant a portion of annexin XI which is capable of reducing inflammation in any in vivo or in vitro assay. Such assays include the in vivo inflammation assay described by Parente, Eur. J. Pharmacol . 99:233, 1984 as well as any phospholipase A 2 inhibition assay, e.g., that described by Wallner et al. (U.S. Patent 4,950,646, hereby incorporated by reference) . In the latter assay, any fragment which inhibits phospholipase A 2 activity is a "phospholipase A 2 -inhibiting fragment"; preferred fragments are those which, when present at a concentration of 1 to 100 μM, decrease phospholipase A 2 activity by at least 25%, and preferably by at least 50%. Detailed Description The drawings are first briefly described. Drawings Fig. 1 depicts the nucleotide sequence (SEQ ID NO: 1) and deduced amino acid sequence (SEQ ID NO: 2) of clone pCTlOl. Nucleotides are numbered from the 5'- proximal ATG, which precedes the single open reading frame. Amino acids are represented by the single letter code. The 3' end of the pCTlOl clone is indicated. The four nucleotides from the end of pCTlOl to the poly(A) tail were derived from the overlapping pCT20 clone; Fig. 2 depicts a comparison between the annexin XI amino acid sequence predicted from pCTlOl and the sequences of two other annexins; Fig. 3 depicts a comparison between the sequence of the SPA (panel A) and EST peptides (panel B) and portions several annexins; Fig. 4 depicts the nucleotide sequence of clone PCT105 (SEQ ID NO:3); Fig. 5 depicts the deduced amino acid sequence of clone pCT105 (SEQ ID N0:4) . The bracketed sequence is present in bovine type II annexin XI, but not in bovine type I annexin XI; Fig. 6 depicts the nucleotide sequences in the regions of the exon-intron junctions of the bovine annexin XI gene. Cloning of Bovine Annexin XI Annexin XI clones were originally isolated from a chondrocyte cDNA lambda gtll library. The largest, pCT20, had an insert approximately half the size of the predominant species detected using this cDNA as a probe on Northern blots of chondrocyte RNA. Analysis of clones indicated that internal EcoRI sites in the cDNAs were not methylated to protect against subsequent digestion by this restriction enzyme during construction of the cDNA library. Subsequently, clones corresponding to full- length mRNA were isolated from an additional chondrocyte cDNA library and a synovial cell cDNA library prepared as described below. Isolation of Total RNA from Bovine Chondrocytes Chondrocytes were isolated by collagenase- digestion from articular cartilage of radial carpal joints of 7 to 11 day old calves according to Towle et al. (Biochem. Biophys . Res . Comm. 121:134, 1984). Cells were washed and resuspended in Dulbecco's modified Eagle's medium (DMEM) with 5% fetal calf serum, and plated at 10 6 cells per cm 2 in 75 cm 2 flasks. Synovial tissue was excised from the same radial carpal joints and cleaned of adherent connective and fat tissue. Minced tissue was incubated for 4 h in 0.08% clostridial collagenase. Partially-digested tissue was rinsed and placed in 75 cm 2 flasks (-2 gm per flask) in DMEM. Cultures were incubated for 3 days during which time synovial cells adhered to the culture flasks. Synovial tissue was removed, medium replaced and cultures incubated until cells appeared confluent. Confluent cells were removed from the flask by trypsin treatment (0.25%) and passaged by dividing cells from one flask into three. Cells were cultured at 37° in a humidified atmosphere of 5% C0 2 95% air. Chondrocytes and synovial cells were maintained in DMEM supplemented with ascorbate (50 μg/ml) , HEPES (10 mM) pH 7.3, penicillin (100 units/ml) , and streptomycin (50 μg/ml) and 10% fetal calf serum except where indicated. Chondrocytes in primary culture were incubated in DMEM containing 5% fetal calf for 24 h. Medium was replaced with serum-free DMEM and incubation continued for 24 h prior to harvesting cells for RNA extraction. Total cellular RNA was extracted from cell cultures using the guanidinium thiocyanate- phenol-chloroform procedure (Chomczynski et al., Anal. Biochem. 162:156, 1987). Preparation of cDNA Libraries Routine manipulations and analysis of nucleic acids were as described by Sambrook et al. (Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989) . Double-stranded cDNA was synthesized using oligo(dT)12-18 as a primer on 5 μg oligo(dT)-selected chondrocyte or synovial cell RNA. Synthesis utilized Moloney murine leukemia virus reverse transcriptase, ribonuclease H and DNA polymerase I using the cDNA synthesis kit from Pharmacia (Piscataway, NJ) . [α 32 P] dCTP was included to monitor cDNA size. Blunt ends were generated with Klenow fragment of DNA polymerase I and the cDNAs ligated with Not I/Eco Rl adapters exactly as described by Pharmacia. Adaptor-modified cDNAs were phosphorylated and size selected on Sepharose 4B (Pharmacia). Double stranded cDNAs larger than -1.4 kb were ligated into dephosphorylated Eco Rl-cut Lambda ZAP II (Stratagene, La Jolla, CA) Recombinant phage were packaged using the Packagene system (Promega, Madison, WI) and plated on XLl-Blue cells. Identification of Annexin XI Clones Annexin XI was initially identified by expression- library screening of a chondrocyte cDNA library in lambda gtll using an antibody to the 57kD latent form of the matrix etalloprotease stromelysin. The antiseru was raised by immunizing a rabbit with stromelysin purified from bovine cartilage-conditioned medium (Treadwell et al., Arch. Biochem . Biophys . 251:724, 1986). The predominant protein in this preparation was stromelysin, but we believe the annexin protein was present as a minor contaminant in the immunizing material. Several cross-hybridizing partial cDNAs were identified in the lambda gtll library and the largest (1.2 kb) was subcloned into pUC19 and M13 vectors for probe generation, restriction analysis and sequencing. Purified cDNA insert from a selected recombinant plasmid (pCT20) was labeled with [α 32 P] dCTP by random-primed synthesis (Feinberg et al., Anal. Biochem . 137:266, 1984) and used to screen un-amplified, size-selected (>1.4 kb) chondrocyte and synovial cell cDNA libraries generated in the lambda ZAP II vector (described above) . Approximately 150,000 independent recombinant phage were screened, and approximately one in 10,000 hybridized with the pCT20 probe (one in 30,000 for the synovial cell library) . Four cDNA clones, with inserts approximately 2300 nucleotides long, were selected for further analysis. Analysis of Positive Clones pBluescript SK(-) phagemids were released from cross-hybridizing clones by the in vivo excision procedure and recovered by plating on XLl-Blue cells grown at 42° in the presence of ampicillin as described by Stratagene. Fragments generated by digestion of each of these cDNAs with restriction endonucleases were analyzed and subcloned into M13mpl8 and M13mpl9 phages. Single stranded DNAs from two clones (pCTlOl and pCT105) were completely sequenσed on both strands by the dideoxy chain-termination method using the primer within M13 or primers based on internal cDNA sequences. Unmodified T7 DNA polymerase in conjunction with deaza-dGTP was used to resolve ambiguous sequence near the 5' end. The cDNAs within pCTlOl and pCT105 were identical except for a short segment, 108 base pairs in pCTlOl and 114 in pCT105, near the 5' end. Additional sequence data (approximately 200 bases in from the internal and flanking Eco Rl sites) were obtained from cross- hybridizing clones. Seouence of Annexin XI cDNAs and Predicted Proteins FIG. 1 shows the amino acid sequence predicted from nucleotide sequence of pCTlOl cDNA. The 2300 base- pair cDNA lacks sequence corresponding to a poly(A) tail but has two potential polyadenylation signals. The two potential polyadenylation signals and putative ribosome binding sites are underlined. A poly(A) sequence terminates pCT20, an overlapping partial clone from the original lambda gtll library corresponding to mRNA polyadenylated downstream from the somewhat unusual signal (AUUAAA) at nucleotide 2182. Clones representing mRNAs polyadenylated at the internal signal (nucleotide 1797) were not found. Furthermore, transcripts detected by Northern blot hybridization were ~2.4 kb and not ~2.2 kb as expected for mRNA utilizing the internal polyadenylation signal. Assuming a poly(A) tail of 100 to 200 nucleotides, pCTlOl appears to be a complete or nearly complete copy of the mRNA. pCT125, cloned from the synovial cell library, is identical to pCTlOl at the 5' end. The most 5'-proximal ATG in pCTlOl exists in a context resembling the consensus sequence for eukaryotic initiation codons (Kozak, J. Mol . Biol . 196:947, 1987). Nucleotides are numbered from this potential initiation codon; however, the surrounding sequence is not optimal for translation initiation, and no upstream termination codon interrupts the open reading frame extending from the 5' end of the cDNA to the TGA at position 1507. It remains possible that pCTlOl and pCT105 cDNAs are incomplete and that the coding region extends beyond the 5' ends of these clones. Assuming that the 5' ATG opens the coding region, a 502 amino acid-protein with a calculated molecular mass of 54,018 daltons (including methionine) and isoelectric point 7.66 is predicted by this cDNA. The deduced protein sequence was used to search protein data bases for similar proteins. DNA and protein sequence data were analyzed using the Genetics Computer Group Sequence Analysis Software " Package. The BLAST Network Service of the National Center for Biotechnology Information was used to search the following protein databases: Protein Identification Resource release 30.0, Swiss Protein release 20.0, and translated GenBank release 70.1, update to 8/30/91. Annexin family proteins were retrieved, those most similar being annexins IV, VII, and the first tetrad of VI (61, 58, and 59% identity, respectively, within the core domain) . Th non-conserved amino terminal domain, however, resembles only annexin VII. This similarity is a reflection of the simple amino acid composition of these domains, which are rich in glycine, tyrosine, and proline with frequent occurrence of the tripeptide tyr-pro-gly. Alignment of annexin XI with sequences of human annexin VII (synexin) and bovine annexin IV is shown in FIG. 2. Annexin repeats in the core domain are aligned and displayed according to the scheme of Pepinsky et al. (J. Biol . Chem. 263:10799, 1988). The amino terminal domains of annexins XI and VII were aligned using the GAP program by the introduction of two gaps (shown as dots) . The 17 amino acid consensus sequence is underlined. Analysis of the deduced annexin XI protein revealed the presence of several characteristic motifs in addition to the annexin repeats. A potential site for asparagine-linked glycosylation exists within the amino terminal domain. However, there is no obvious signal sequence, and analysis of the protein in cell extracts using anti-peptide antibodies (see below) indicated an intracellular localization. Numerous serine and threonine residues are potential targets for phosphorylation by protein kinase C and casein kinase II. Whether these sites are actually phosphorylated has not been determined. Characterization of Annexin XI Using Anti-Peptide Antisera In order to identify annexin XI protein in cells, antisera were generated against two peptides predicted from sequence of pCTlOl cDNA (the sequences of the peptides are double-underlined in FIG. 2) . Peptides were synthesized corresponding to a sequence in the amino terminal domain (SPA peptide: amino acids 181-193 of pCTlOl) and a sequence in the connecting peptide between the second and third repeat of the annexin core domain (EST peptide: amino acids 345-357 of pCTlOl) , both non-conserved regions among annexins. FIG. 3 illustrates a comparison of the annexin XI sequences used for synthetic peptides with other annexin proteins and shows that these peptides are derived from regions which are not conserved among annexins. To generate this figure, the annexin XI sequence was aligned using the Bestfit program with sequences of other annexins. Human lipocortins (annexins) I, III and V (Pepinsky et al. (supra) , annexin VI (Sudhof et al., Proc . Natl . Acad. U.S.A., 85:664, 1988), synexin (annexin VII) (Burns et al., Proc. Natl . Acad . Sci . U. S .A . 86:3798, 1989), and VAC- / 3 (annexin VIII) (Haupt ann et al., JEur. J. Biochem. 185:63, 1989) and bovine sequences for calpactin I heavy chain (annexin II) (Kristensen et al., Biochemistry 25:4497, 1986) and annexin IV (Hamman et al. , Biochem. Biophys . Res . Comm . , 156:660, 1988) are shown. Shaded residues correspond to positions of identity between the respective protein and the synthetic peptide. Asterisks indicate residues not present in the short amino terminal domains of annexins IV and V, which initiate within the range of the peptides. The peptides were separately conjugated to KLH using MBS (Harlow et al. , Antibodies : A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, Harbor, NY, 1988) . Cysteine residues were added to the carboxy terminus of each peptide for the ' purpose of coupling to carrier protein. Rabbits were immunized according to the following protocol. Three rabbits were injected subcutaneously with each peptide-KLH conjugate (150 to 200 μq peptide) emulsified in complete Freund's adjuvant; at 21-day intervals, animals were boosted with the same antigens in incomplete Freund's adjuvant. They were bled 10 days after injection and the sera tested by direct binding enzyme-linked immunosorbent assay using a 96-well plate coated with -50 ng free peptide per well. Peptides were conjugated directly to Aminoethyl Bio-Gel P2 (BioRad Laboratories) (Cole et al., Cell 64:703, 1991). Briefly, 50 μl MBS (25 mg/ml in dimethyl formamide) was added to 10 mg resin (hydrated according to manufacturers recommendations) in 1.0 ml lOmM KP0 4 pH 7.4. Resin was mixed gently for 1 h, washed with ice- cold phosphate buffer, and resuspended in 0.5 ml lOmM HEPES (pH 6.6) containing 1 mg synthetic peptide. Conjugation proceeded for 3 h. 2-mercaptoethanol was added to a concentration of lOmM, and after 30 min, the resin was washed with 20mM TRIS-HC1, l50mM NaCl, 0.02% NaN 3 pH 7.8 (TBS) . 200 μl antiserum was diluted to 10 ml with TBST (TBS with 0.05% Tween 20) and mixed for 1 h with the respective resin conjugate. The resin was washed with five volumes of TBST. Bound antibody was eluted with 250 l glycine HCl, lOOmM NaCl pH 2.5 and neutralized with Tris base. The rabbit antisera were evaluated by i munoblot analysis of chondrocyte extracts and immuno-precipitation of annexin XI translated from RNA transcribed in vitro from pCTlOl. For immunoblot analysis proteins which were extracted from chondrocyte monolayer cultures with EGTA and Triton X-100 were reduced and resolved (200 μg per lane) on SDS 9% polyacryla ide gels. Proteins were transferred to Immobilon and visualized by immunochemical staining using antiserum to SPA-peptide at 1:3,500 dilution as a primary antibody, the same antiserum pre- incubated 15 min with 5 μg SPA peptide, antibody affinity-purified from the same antiserum on SPA-peptide conjugated to amino-ethyl resin, antiserum to the EST- peptide at 1:1000 dilution, and the same antiserum preincubated with 5 μg of the EST-peptide, antibody affinity-purified from the same antiserum using the EST- peptide-resin conjugate or by staining with Coomassie Blue. Phosphorylase b (92 kDa) bovine serum albumin (68 kDa) , ovalbumin (45 kDa), and carbonic anhydrase (30 kDa) were used to estimate molecular mass. For protein translated in the presence of [ 35 SJ methionine from RNA transcribed in vitro from pCTlOl RNA was immunoprecipitated as described using anti-peptide antisera and resolved by SDS-PAGE. Antiserum to SPA- peptide, the same antiserum preincubated with 5 μg SPA- peptide, the same antiserum preincubated with 5 μg SPA- peptide, antiserum to EST-peptide, or the same antiserum preincubated with 5 μg EST-peptide. Antisera prepared against the two synthetic peptides each identified a -56 kDa protein in chondrocyte extracts. The anti-SPA serum reacted very strongly and quite specifically with this protein on immunoblots, while un-purified anti-EST serum recognized multiple proteins in addition to the -56 kDa protein. The protein translated from RNA transcribed in vitro from pCTlOl co- migrated on SDS-page with the ~56 kDa immunoreactive chondrocyte protein and was immunoprecipitated by each antiserum. Furthermore, preincubation of each antiserum with the corresponding free peptide prevented both i munoprecipitation and detection of protein on immunoblots. These results demonstrate the specificity of the anti-peptide antisera and identify a chondrocyte protein, ~56,000 molecular weight, as annexin XI. Tissue Distribution of Annexin XI Northern blot analysis of chondrocyte RNA demonstrated that pCTlOl cDNA probes hybridized to produce a single major signal slightly above 2.4 kb. (A minor signal occasionally visible near the position of 28 S ribosomal RNA probably represents unprocessed or partially-processed transcript, since it was not evident in oligo-dT-selected RNA.) Annexin XI transcripts were present at comparable levels in a variety of specialized bovine cells including chondrocytes, synovial cells at third passage, SBAC adrenal cortical cells, and MDBK kidney epithelial cells. Annexin XI was identified among proteins extracted from bovine cells using anti-peptide antibodies on immunoblots. The -56 kDa protein was present in approximately equal relative abundance in EGTA-Triton extracts prepared from each cell type. Protocols for Northern blot analysis and immunoblot analysis are described below. In vitro Transcription and Translation Annexin XI recombinant plasmid pCTlOl was linearized by digestion with Hind III, which cleaves within the multiple cloning site downstream from the cDNA insert. One μg plasmid was transcribed using T3 RNA polymerase and the Pharmacia in vitro transcription kit following the recommendations of the supplier for the 7- ethyl guanosine capping protocol and DNAase I digestion. Reaction products were extracted with phenol and chloroform, precipitated with sodium acetate and ethanol, and dissolved in 20 μl water. One μl of RNA was translated 60 min at 37° in a 10 μl reaction using micrococcal nuclease-treated rabbit reticulocyte lysate (Promega) supplemented with [ 35 S] methionine. Preparation of Cell Extracts Chondrocytes and cells from established bovine cell lines were placed in 75 cm 2 flasks and cultured for 3 days, medium being changed 24 h before extraction of cell proteins. Protein extraction from confluent monolayers was performed on ice. Cells were washed twice with serum-free minimal Eagle's medium. Five ml buffer A (TBS with 10 mM EGTA) was added to each flask. The protein in the "EGTA extract" was recovered after 5 min. Five ml buffer A containing 0.5 Triton X-100 was added to each flask, and after 5 min the "EGTA-Triton" extract was recovered. Protein solutions were stored in aliquots at -40° prior to immunoblot analysis. Immunoprecipitation Translation products were diluted to 100 μl with SDS-PAGE sample buffer containing 1% 2-mercaptoethanol and boiled for 3 min. Samples were centrifuged 12,000g 5 min and the supernatants diluted with four volumes of TBS containing 1% Triton x-100, 0.5% Tween 20, lOmM EDTA, 1 μg/ml aprotinin. Antiserum (2 μl) was added, mixtures were incubated for 1 h, and the immune complexes were captured on protein A Sepharose. Beads were washed with the same buffer. Four bovine cell lines were obtained as frozen cells from American Type Culture Collection, Rockville, MD. These cell lines are described by the supplier as follows: SBAC is a normal endocrine cell line derived from adrenal cortex and responsive to adrenocorticotropic hormone. CPAE are normal endothelial cells derived from pulmonary artery and possessing angiotensin-converting enzyme activity. MDBK are hypo- diploid kidney cells of epithelial-like morphology. EBTr cells are normal and hypo-diploid fibroblast-like cells derived from embryonic trachea. Frozen cells were thawed and diluted to 3 X 10 5 cells/ml in minimum essential Eagle's medium with non- essential amino acids and Earle's balanced salt solution. Medium was supplemented with heat inactivated newborn calf serum at 10% (20% for CPAE cells) . Cells were cultured in 75 cm 2 flasks, with media changes at three- day intervals, until confluent. Cells were passaged as for synovial cells. Isolation of RNA Synovial cells (third passage) and cells „from bovine cell lines were incubated three days after sub- culturing, medium being replaced 24 h before extraction of RNA for Northern blot analysis. Northern blot analysis Ten to 15 μg total RNA was resolved on 1% agarose formaldehyde gels and transferred to nitrocellulose by capillary blotting. Blots were baked under vacuum and prehybridized in 5x SSPE (IX is 180mM NaCl, lOmM NaP0 4 , 1 mM EDTA, pH 7.7), 50% formamide, 1% N-lauryl sarcosine, lx Denhardt's (Ficoll, polyvinyl pyrrolidone, and bovine serum albumin each at 0.02%), and 100 μg/ml boiled, sonicated salmon sperm DNA. cDNA inserts of plasmids were purified on low gel-temperature agarose and labeled with [α 32 p]dCTP by random primed synthesis (Feinberg et al., supra) . Probes were denatured by boiling and added at 10 ng/ml to the same buffer used for hybridization. Hybridization was for 18 h at 42°. Blots were washed at 65° with 0.2X SSPE 1% N lauryl sarcosine. Nitrocellulose was exposed to X-ray film with intensifying screen at - 40°C for 1-3 days. SDS polyacrylamide gel electrophoresis Proteins present in acetone- or immuno- precipitates, were solubilized by boiling 3 min in 25 μl SDS sample buffer containing 2% 2-mercaptoethanol. Proteins were resolved on 9% polyacrylamide gels. Immunoblot analysis Gels were equilibrated with 20mM Tris base, 150mM glycine, 15% methanol and the resolved proteins electrophoretically transferred to Immobilon. Membranes were blocked by incubation for 1 hr at 37° in 3% gelatin prepared in TBS. Membranes were incubated for 1 hr with antisera or affinity-purified anti-peptide antibodies (10 to 50 ng per ml in TBST 1% gelatin) , washed with TBST, and incubated 1 hr with 1:7500 dilution of alkaline phosphatase-conjugated goat anti-rabbit IgG (Promega) . The blots were washed with TBST and developed with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate as the chromogenic substrate. Modification of Annexin XI There is a potential site of N-linked glycosylation within the amino terminal domain. To determine whether annexin XI protein was glycosylated on asparagine, protein extracted from chondrocytes by EGTA and Triton X-100 was incubated with N-glycanase and then subjected to immunoblot analysis using anti-peptide antibodies. Enzymatic treatment did not alter the mobility of the immunoreactive species on SDS-PAGE. Furthermore, annexin XI was undetectable in chondrocyte culture medium or the EGTA-extract of live cells but was extracted by EGTA in the absence of detergent from hypotonically-lysed chondrocytes (results not shown) . These observations suggest that annexin XI was predominantly intracellular. Characterization of Alternatively Spliced Forms of Annexin XI Described below are a series of experiments demonstrating the existence of alternatively spliced annexin XI transcripts capable of encoding proteins which differ near the amino terminus. Clones pCTlOl and pCT105 represent these distinct forms of bovine annexin XI (type I and type II respectively) . The pCT105 and pCTlOl cDNAs were identical except for a short segment, 109 bp in pCTlOl and 115 bp in pCT105, where the two sequences were completely different; this sequence divergence within the pCTlOl coding regions did not disrupt the reading frame. Translation of the two species of mRNA would result in two kinds of annexin XI proteins differing at the amino terminal ends. Fig. 4 depicts the partial nucleotide (SEQ ID NO: 3) of the pCT105 cDNA clone; Fig. 5 depicts the deduced amino acid sequence (SEQ ID NO: 4) of the pCT105 cDNA clone. The 5' proximal ATG common to both annexin XI cDNAs approximates the consensus initiation context defined by Kozak (J. Mol. Biol . 196:947, 1987). This is most likely used to initiate the type I protein, since alternative sites would result in a protein substantially different in size from the ~56 kDa annexin XI identified by immunoblotting using anti-peptide antisera. However, three additional in frame methionine codons exist within the variant region of the type II mRNA, and one conforms even more closely to the consensus initiation sequence. Should this alternative site be utilized for translation initiation, the product would be a -49 kD polypeptide. This polypeptide would include a stretch of twelve neutral, mostly hydrophobic residues near the amino terminus. The sequence weakly conforms to the consensus signal sequence defined by von Heijne (J . Mol . Biol . 184:99, 1985), suggesting that at least some annexin XI may be secreted by the conventional route to function extracellularly. The antibodies described above would recognize both forms of annexin XI and therefore cannot be used to determine whether both transcripts are translated.- The two proteins could be distinguished by size if the internal methionine codon initiated translation of the type II protein. Immunoblot analysis of bovine chondrocyte extracts using anti-peptide antisera described above identified a 56 kDa protein. A minor 50 kDa protein visible on a blot from an over-loaded (500 μg protein) SDS polyacrylamide gel may represent type II protein or a type I degradation product. Anti-peptide antisera based on the sequence predicted from the variant regions of pCTlOl and pCT105 can likely be used for analysis of the two annexin XI isoforms. Expression of Annexin XI Transcripts Type I and type II specific labeled oligonucleotide probes were used in an attempt to identify the two annexin XI transcripts by Northern blot analysis. Type I transcripts were readily visualized; however, type II transcripts were not observed, even on blots of 20 μg polyA + chondrocyte RNA. Accordingly, type II mRNA, if present, is expressed at much lower levels than type I mRNA in this cell type. In order to verify that the pCT105. clone represented an annexin XI transcript, cDNAs reverse transcribed from chondrocyte or MDBK cell RNA were analyzed by polymerase chain reaction (PCR) amplification. The strategy was to co-amplify cDNAs derived from the two classes of mRNA using pairs of primers that span the region of sequence divergence identified in the pCTlOl and pCT105 clones. To increase the specificity of PCR, we carried out two sequential sets of 28- cycle reactions using different pairs of specific primers. The following oligonucleotides were used for PCR analysis: A: AGATCTAGCCATGAGCTCCCCAGGCTACC (SEQ ID NO:5) common to pCTlOl and pCT105 B: CCCGCAGGTGGCTAGCCACCAGGT (SEQ- ID NO:6) common to PCTlOl and pCT105 C: AGGTTTGGCACGTTGGATCCTCCAA (SEQ ID NO:7) common to pCTlOl and pCT105 (antisense) D: CAACTATGCAGGGCAGTTCAACCA (SEQ ID NO:8) pCTlOl specific E: CCACATTATCCAGCCCAATGGGAGGCA (SEQ ID NO:9) pCTlOl specific (antisense) F: AGCTGGAAAGCCACGCTGGAGGCC (SEQ ID NO:10) pCT105 specific G: TGGACAGGGCTGTTTCTGACGGGCC (SEQ ID NO:11) pCT105 specific H: CAAGTAGCACAGCAGCTAGCATCATGGC (SEQ ID NO:12) pCT105 specific (antisense) Restriction sites introduced to facilitate cloning of PCR products are underlined. All oligonucleotides were purchased from Oligos Etc. (Medford, OR) . Some of these oligonucleotides were also used as sequencing primers and hybridization probes for anlysis of PCR products and clones. PCR amplifications were carried out in a Biosycler thermal cycler (Bios Corp., New Haven, CT) . Reaction mixtures (100 μl) contained 100 pmol of each primer, 200 μM each of the four deoxynucleoside triphosphates, 5 units Tag polymerase (Promega, Madison, WI) , and template; the buffer supplied by Promega was optimized with respect to Mg +2 concentration for each primer pair using cDNA templates. Aliquots of PCR products, untreated or digested with restriction endonucleases that cut within the variant regions of pCTlOl and pCT105, were resolved by agarose gel electrophoresis and transferred to Biotrans nylon membranes (ICN, Irvine, CA) . Oligonucleotides designed from the variant region sequences (D-H) were labeled at the 5'-ends using T4 polynucleotide kinase for use as hybridization probes. Cell culture and RNA extraction were as described above. Complimentary DNA was synthesized in a 15 μl reaction using Moloney murine leukemia virus reverse transcriptase and the first strand cDNA synthesis kit from Pharmacia (Piscataway, NJ) . The supplied Notl-oligo d(T)18 oligonucleotide served to prime synthesis on 3 μg total RNA from chondrocytes or MDBK (bovine kidney epithelial) cells. The resulting single strand cDNAs (5 μl) were templates for PCR using primers (A and C) that span the segment of sequence divergence between the pCTlOl and pCT105 cDNA clones. Amplification was for 28 cycles, each consisting of a 30 sec denaturation step (94°), a 30- sec annealing (56°) step, and a 30 sec extension (72°) step. One μl of each product was further amplified through 28- cycles (same profile) using primers B and C. In order to specifically amplify the low abundance type II mRNA, pairs of primers, one specific to pCT105 and one common to both cDNAs (A and H or F and C) , were used to re-amplify the product of the first PCR (5 μl) . DNA synthesized in the reactions was analyzed by restriction endonuclease digestion and Southern blot hybridization. The amplified products and restriction fragments visualized by autoradiography were the sizes expected from cDNA sequences of pCTlOl and pCT105. These data provide strong evidence for the presence of both classes of annexin XI transcripts in MDBK cells and chondrocytes. Because the efficiency of reverse transcriptase varies with the template, this PCR assay can not be considered quantitative. However, these results taken with the fact that type II species could not be detected on Northern blots, suggest that the type II transcript is a minor mRNA in these cells. Alternative Splicing Generates Two Classes of Annexin XI mRNA (Type I and Type II) . Alternative splicing of identical annexin XI primary transcripts could generate the mRNA diversity indicated by the pCTlOl and pCT105 cDNA clones. In order to determine whether the two variant sequences are encoded by the same region of the genome, various pair- wise combinations of primers corresponding to the divergent and common regions of pCTlOl and pCT105 were used to amplify bovine genomic DNA by PCR. PCR products were digested with restriction endonucleases specific to each putative exon, and the resulting DNA fragments were resolved by agarose gel electrophoresis were analyzed by Southern blot hybridization. The first amplification reaction contained 100 pmol each of 5' primer A and 3' primer C with 10 μg bovine genomic DNA (Clonetech, Palo Alto, CA) as template. Three cycles of 1 min denaturation (94°), 30 sec annealing (56°), 2.5 min extension (72°) were followed by 25 cycles with the same parameters except that the denaturation time was 30 sec. The product (5 μ.1) of the first PCR amplification was used as the template in a second amplification (same parameters) employing 100 pmol each of primers B and C. The major product of the second amplification reaction, -2.5 kb, was cloned as two restriction fragments into pGEM3z (Pro ega, Madison, WI) . Aliquots of the reaction mixture containing 200 ng of the 2.5 kb DNA were digested with Nhel for cloning into Xbal- digested pGEM3z or with Nhel plus BamHI for ligation into Xbal and BamHI digested vector. Restriction digests were heat-inactivated, passed over Chro aspin 400 (Clontech, Palo Alto, CA) , ethanol precipitated and ligated with appropriately digested vector. Competent DH5α cells (BRL, Bethesda, MD) were transformed, and transformants were selected on ampicillin plates. Positive colonies were identified by standard hybridization techniques using oligonucleotides labeled at the 5' end. These experiments established that: 1) a genomic fragment ~2.5 kb was amplified by primers designed from sequence spanning the variant regions of pCTlOl and pCT105; 2) restriction endonucleases specific to each of the variant regions cleaved the PCR products, and 3) the deduced order of putative exons in the gene is 5' common, type II-specific, type I-specific, and 3' common. Primers bracketing the variant segment of pCTlOl and pCT105 cDNAs were used to amplify the region of the annexin XI gene containing the two putative alternatively spliced exons. The -2.5 kb PCR product was cloned, and the cloned DNA was sequenced. Fig. 6 depicts the nucleotide sequences in the regions of exon-intron junctions as determined by sequencing PCR clones. Exons and introns were identified by comparison of the cDNA sequences with that of the cloned genomic PCR product. This analysis confirms that the type I-specific and type II-specific sequences are arranged as neighboring discrete exons in the bovine genome. The exon/intron junctions are in good agreement with consensus sequences for these regions (Mount, Nucl . Acids Res . 10:459, 1982). Split codons, G at the 3' boundary of the 5' common exon spliced to GU of the type I- specific and type II-specific exons, encode the glycine residue that precedes the divergence of the two annexin XI deduced proteins. The 3' borders of these exons separate (rather than split) codons, as does the 5' border of the 3' common exon. Thus, either of the two specific exons serve as the adaptor necessary to join the 5' and 3' common exons without shifting the reading frame. The primary transcript of a single annexin XI gene can apparently be processed into either of two different mRNAs, each having one of two specific exons. Such alternative splicing, the mutually-exclusive utilization of exons in the processed RNA, in most cases has evolved from an exon duplication event (Breitbart et al., Ann . Rev. Biochem. 56:467, 1987). While we have described alternative RNA splicing as a means of generating two annexin XI gene products our experiments do not exhaust the possibilities for additional splicing variants. Alternative splicing of annexin XI may be regulated. If so, identification of conditions associated with elevated expression of the type II species might provide a clue to the function(s) of this novel annexin. Such conditions would also facilitate an examination of the biosynthetic processing of the two types of protein. Cloning of Human Annexin XI Human annexin XI can be easily cloned from an appropriate cDNA library using bovine annexin XI cDNA as a probe. Suitable cDNA libraries include: human monoσyte, U937 cells, phorbol myristate-stimulated, human adrenal, and human kidney (Clontech, Palo Alto, CA) . Purified cDNA insert from pCTlOl or pCT105 can be labeled with [α 32 P]dNTP by random-primed synthesis (Feinberg et al. , supra) and used to screen an appropriate human cDNA library. Positive clones can be sequenced and should have >80% homology to bovine annexin XI. In an alternative approach, oligonucleotide probes, designed based on the sequence of bovine annexin XI (SEQ ID NO:l), can be used to isolate a bovine annexin XI clone from a bovine chondrocyte cDNA library. This bovine annexin XI clone can be used in place of pCTlOl or pCT105 cDNA to isolate human annexin XI. Oligonucleotide probes, designed based on the sequence of bovine annexin XI (SEQ ID N0:1) may be used to directly screen a human cDNA library as described above. Those skilled in the art will recognize that the probes should be selected from regions of bovine annexin XI that are not significantly homologous to other annexins (e.g., annexin VII or annexin IV) . In another alternative approach, the oligonucleotide primers described above (SEQ ID NO:5 and SEQ ID NO: 7) can be used to amplify a human annexin XI fragment from human genomic DNA (e.g., available from Clontech, Palo Alto, CA) by polymerase chain reaction. The amplified fragment is then 32 P-labeled, e.g., by the random-primed synthesis method of Feinberg et al. (supra) and used to probe a human genomic (e.g., a human leukocyte) DNA library in order to isolate the full- length human annexin XI clone. Biologically Active Polypeptides Polypeptide fragments of annexin XI can be generated by proteolysis. Limited or complete proteolysis by elastase or proteinase K can be used to generate fragments of varied length since they hydrolyze peptide bonds rather non-specifically. Plasmin and other proteases which hydrolyze peptide bonds in a more structure and sequence dependent manner may also be used to generate useful polypeptide fragments. Polypeptide fragments generated by proteolytic digestion can be isolated by column chromatography. Fragments may also be produced by genetic engineering techniques or by standard techniques of chemical peptide synthesis. Desirable polypeptide fragments are those which inhibit inflammation. Such fragments may, e.g., inhibit phospholipase A 2 activity, as measured, e.g., using the assay described by Wallner et al. (U.S. Patent 4,950,646 or they may inhibit in vivo inflammation as assayed by the method of Parente (Eur. J. Pharmacol . 99:233, 1984; hereby incorporated by reference) . Other desirable polypeptide fragments inhibit coagulation. Coagulation inhibiting activity can be measured using the assay described by Reutelingsperger et al. (JEfur. J. Biochem. 151:625, 1985). Use Because annexins inhibit phospholipase A 2 activity, annexin XI and polypeptide fragments thereof will be useful for reducing inflammation associated with arthritis, allergies, dermatologic disorders, ophthalmic disorders, and collagen diseases. In addition, since annexins have anti-coagulant activity, annexin XI and polypeptide fragments thereof will be useful for inhibiting coagulation. The polypeptides of the invention can be administered in an effective amount either alone or in combination with a pharmaceutically acceptable carrier or diluent. The polypeptides and compositions can be administered alone or in combination with other therapeutic agents. If appropriate, multiple therapeutic annexin XI peptides (e.g. , multiple biologically-active annexin XI fragments) may be administered either simultaneously or sequentially. The polypeptides and compositions of the invention may be administered by any convenient means, e.g., intravenously, intra-articularly, orally, intramuscularly, or intranasally. Annexin XI and immunogenic polypeptide fragments thereof can be used to screen for autoantibodies associated with a variety of pathological states. Similarly, antibodies raised against annexin XI and immunogenic polypeptide fragments thereof can be used to measure annexin XI levels in synovial fluid for the purpose of detecting pathologic conditions. Such antibodies can be used in any standard format such as a radioimmunoassay, an ELISA assay, or a Western blot. Increased levels of anti-annexin XI autoantibodies may be present in patients treated with corticosteroids (e.g., patients receiving corticosteroids as a treatment for inflammatory diseases such as rheumatoid arthritis) . It has been proposed that autoantibodies against another annexin (lipocortin-1) are responsible for "steroid resistance" in patients receiving prolonged treatment with corticosteroids (Goulding et al.. Annals Rheum . Diseases 48:843, 1989). Accordingly, monitoring of anti- annexin XI autoantibodies may provide a means by which to monitor corticosteroid treatment. Increased levels of anti-annexin XI autoantibodies may also be present in patients with inflammatory diseases such as systemic lupus erythe atosus. Detection of such autoantibodies using annexin XI may be useful in diagnosis of inflammatory diseases. Annexin XI can be used in a radioimmunoassay, an ELISA assay, a Western blot, or any other standard format immunoassay to measure anti-annexin autoantibody levels in human sera or synovial fluid. Such assays might employ annexin XI and detectably labeled rabbit antihuman IgM or rabbit antihuman IgG antibody. Anti-annexin XI antibodies can be used in a standard immunoassay to measure annexin XI levels in human sera of synovial fluid. Altered annexin XI levels may be associated with a number of inflammatory diseases such as arthritis. Other Embodiments Antibodies capable of specifically forming an immune complex with annexin XI can be produced by standard techniques (see Harlow et al, supra) using intact annexin XI or immunogenic fragments thereof. Annexin XI fragments can be generated by digestion of annexin XI with proteases or by synthesizing peptides chemically. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Towle, Christine A. et al. (ii) TITLE OF INVENTION: ANNEXIN XI (iii) NUMBER OF SEQUENCES: 12 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Fish & Richardson (B) STREET: 225 Franklin Street (C) CITY: Boston (D) STATE: Massachusetts (E) COUNTRY: U.S.A. (F) ZIP: 02110-2804 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb (B) COMPUTER: IBM PS/2 Model 50Z or 55SX (C) OPERATING SYSTEM: IBM P.C DOS (Version 3.30) (D) SOFTWARE: WordPerfect (Version 5.0) (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 07/764,465 (B) FILING DATE: September 23, 1991 (A) APPLICATION NUMBER: 07/837,775 (B) FILING DATE: February 13, 1992 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Clark, Paul T. (B) REGISTRATION NUMBER: 30,162 (C) REFERENCE/DOCKET NUMBER: 00786/099001 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (617) 542-5070 (B) TELEFAX: (61 ) 542-8906 (C) TELEX: 200154 (2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2305 (B) TYPE: nucleic acid (C) STRANDEDNESS: single CD) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: TCGGAGGTGC TGCGCCTGGG ACGCCCGGAG AGAGAGCTGC TTCTGCCCGC 50 GTCCCACGTC TCCCCTCGCG ACTCCCCACT GCCCCGTGGC CAGATCTAGC 100 C 101 ATG AGC TAC CCA GGC TAC CCC CCG CCC GCA GGT GGC TAC CCA CCA 146 GGT GCA CCA GGT GGC GGT GCC TGG GGA GGT GCT GGC TAC CCG CCA 191 CCC ACC ATG CCT CCC ATT GGG CTG GAT AAT GTG GCC AAC TAT GCA 236 GGG CAG TTC AAC CAG GAC TAC CTC TCA GGA GTG GCG GCC AAC ATG 281 TCC GGG ACG TTT GGA GGA GCC AAC GCC CCT GGG GGT GGT TAC CCC CCA CAG CCC CCT CCC GCC CAG CAG CCT CCG CCC CCT GGA GGA AAC CCC ACC CCA TAC CCA GGG GCC CCT GTG CCA GGA CAG CAG CCC CCA GGG GTC TAC TAC CCT GGA CAG TCA CCA GTG CCA CCA AGC TAT CCA GGG TAC TCA GGT GTG TCC CCC GCT CAG TTT GGA AAC CGA GGC ACC ATC ACA GAT GCA 686 TCT GGC TTT GAC CCC CTG CGA GAT GCT GAA GTC CTG CGG AAG GCC 731 ATG AAG GGC TTT GGG ACT GAC GAG CAG GCC ATC ATT GAC TGC CTG 776 GGT AGT CGC TCC AAC AAG CAA CGA CAG CAG ATC CTC CTG TCG TTC 821 AAG ACA GCA TAT GGG AAG GAT TTG ATC AAA GAT CTG AAA TCT GAA 866 CTG TCA GGA AAC TTT GAG AAG ACA ATC TTG GCC CTG ATG AAG ACC 911 CCT GTC CTC TTT GAC GCT TAT GAG ATA AAG GAA GCT ATC AAG GGG 956 GCG GGC ACT GAT GAA GCC TGC CTG ATC GAG ATC CTG GCC TCC CGC 1001 AGC AAC GAG CAC ATC CGG GAG CTG AAC AGA GTC TAC AAG ACA GAA 1046 TTC AAA AAG ACC CTG GAG GAG GCC ATT CGG AGC GAC ACT TCA GGG 1091 CAC TTC CAG CGG CTC CTC ATC TCT CTC TCT CAG GGA AAC CGG GAT 1136 GAA AGC ACA AAC GTG GAC ATG ACC CTT GTC CAG AGA GAT GTG CAG 1181 GAG CTC TAT GCA GCT GGG GAG AAC CGC CTG GGA ACA GAT GAG TCC 1226 AAG TTC AAT GCG ATT CTG TGC TCC CGG AGC CGG GCC CAC CTG GTG 1271 GCA GTT TTT AAC GAG TAT CAG AGG ATG ACA GGA CGT GAC ATT GAG 1316 AAG AGC ATC TGC CGG GAG ATG TCC GGG GAC CTG GAG CAG GGC ATG 1361 CTG GCT GTG GTG AAA TGT CTT AAG AAT ACC CCA GCC TTC TTT GCT 1406 GAA AGG CTC AAC AAG GCC ATG AGG GGA GCC GGA ACC AAA GAC CGG 1451 ACC CTG ATC CGC ATC ATG GTG TCT CGC AGC GAG ATC GAC CTC CTG 1496 GAC ATC AGA GCA GAG TAT AAG CGG CTG TAT GGC AAG TCG CTG TAC 1541 CAC GAC ATC ACG GGA GAC ACT TCA GGG GAT TAC CGG AAG ATT CTG 1586 CTG AAG ATC TGT GGT GGC AAT GAC TGAGCAGTG 1619 GCTGGTGGGT CACTTCTGTC CACCTGCTGG CAACAGCAAT GCCAGGAAAA 1669 GGCCAAAAGA ACGTTTGTCT GTTTCTAACA AATCTACAAA GTAGCCCCCA 1719 GGTGTCACAG TTCAGACCAA CTGTAGAGCC TTGGCCCCAT CTCCTCCCCC 1769 GCCCTCGATC CGTGCATTGT GCTTGTGCCC GAGAACCTAG TCAGTCTCGA 1819 ACTCTCTCAG GACGCCTCCT CCCCATCCCG ACCCCTCACA GCCTCTTGCA 1869 GCTTAAAGTA GATGTTTTGT TCCTGAAAAA TAAACTCTGG CTTCCTCTAG 1919 TCATGTAGTT TTGTATGTTT AGAGGTTTTT TTTTTTTTTT TAATAATTAG 1969 TTGCAGACAG TTGCATACAC ATCTTTGCTG CATACAAAGT TTGGATAAAA 2019 GAGGTGGGGG GTTGGAGTGC CATGTCTTCA CTGAGGAGTA AAAGGAAAAC 2069 TTTCAGGATA GACTCTGCAT CTGGTGAAAA TGTGTCATGA GCTTTGTTGT 2119 TGCCAAACTC ACTCCTTTTT AGAAAAGAAA AGGCCAGAAA GTCATCTGTT 2169 CTTTCTTCTA CACAAACCAC AAGAACAAAG CCAGCTCCCT GCCAGTGACA 2219 GGGCTTCTTG TAATTGAGAA TGTGCCTTAA CCTGAATGTT GATGGCCAAA 2269 TGCTGTTTCC AAATTAAAGT CTGCCAGCTC TGAAAA 2305 (2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 503 (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Met Ser Tyr Pro Gly Tyr Pro Pro Pro Ala Gly Gly Tyr Pro Pro 5 10 15 Gly Ala Pro Gly Gly Gly Ala Trp Gly Gly Ala Gly Tyr Pro Pro 20 25 30 Pro Thr Met Pro Pro lie Gly Leu Asp Asn Val Ala Asn Tyr Ala 35 40 45 Gly Gin Phe Asn Gin Asp Tyr Leu Ser Gly Val Ala Ala Asn Met 50 55 60 Ser Gly Thr Phe Gly Gly Ala Asn Val Pro Asn Leu Tyr Pro Gly 65 70 75 Ala Pro Gly Gly Gly Tyr Pro Pro Val Pro Pro Gly Gly Phe Gly 80 85 90 Gin Pro Pro Pro Ala Gin Gin Pro Val Pro Ser Tyr Gly Met Tyr 95 100 105 Pro Pro Pro Gly Gly Asn Pro Thr Ser Gly Met Pro Ser Tyr Pro 110 115 120 Pro Tyr Pro Gly Ala Pro Val Pro Gly Gin Pro Met Leu Pro Pro 125 130 135 Gly Gin Gin Pro Pro Gly Val Tyr Pro Gly Gin Pro Pro Met Thr 140 145 150 Tyr Pro Gly Gin Ser Pro Val Pro Pro Pro Gly Gin Gin Pro Val 155 160 165 Pro Ser Tyr Pro Gly Tyr Ser Gly Ser Gly Thr Val Thr Pro Ala 170 175 180 Val Ser Pro Ala Gin Phe Gly Asn Arg Gly Thr lie Thr Asp Ala 185 190 195 Ser Gly Phe Asp Pro Leu Arg Asp Ala Glu Val Leu Arg Lys Ala 200 205 210 Met Lys Gly Phe Gly Thr Asp Glu Gin Ala lie lie Asp Cys Leu 215 220 225 Gly Ser Arg Ser Asn Lys Gin Arg Gin Gin lie Leu Leu Ser Phe 230 235 240 Lys Thr Ala Tyr Gly Lys Asp Leu lie Lys Asp Leu Lys Ser Glu 245 250 255 Leu Ser Gly Asn Phe Glu Lys Thr lie Leu Ala Leu Met Lys Thr 260 265 270 Pro Val Leu Phe Asp Ala Tyr Glu lie Lys Glu Ala lie Lys Gly 275 280 285 Ala Gly Thr Asp Glu Ala Cys Leu lie Glu lie Leu Ala Ser Arg 290 295 300 Ser Asn Glu His lie Arg Glu Leu Asn Arg Val Tyr Lys Thr Glu 305 310 315 Phe Lys Lys Thr Leu Glu Glu Ala lie Arg Ser Asp Thr Ser Gly 320 325 330 His Phe Gin Arg Leu Leu lie Ser Leu Ser Gin Gly Asn Arg Asp 335 340 345 Glu Ser Thr Asn Val Asp Met Thr Leu Val Gin Arg Asp Val Gin 350 355 360 Glu Leu Tyr Ala Ala Gly Glu Asn Arg Leu Gly Thr Asp Glu Ser 365 370 375 Lys Phe Asn Ala lie Leu Cys Ser Arg Ser Arg Ala His Leu Val 380 385 .390 Ala Val Phe Asn Glu Tyr Gin Arg Met Thr Gly Arg Asp lie Glu (2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3261 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear Cxi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: TCGGAGGTGC TGCGCCTGGG ACGCCCGGAG AGAGAGCTGC TTCTGCCCGC 50 GTCCCACGTC TCCCCTCGCG ACTCCCCACT GCCCCGTGGC CAGATCTAGC 100 CATGAGCTAC CCAGGCTACC CCCCGCCCGC AGGTGGCTAC CCACCAGGTG 150 CACCAGGTGT CCCGGAGCTG GAAAGCCACG CTGGAGGCCC CCAGGGCCTT 200 TTCGCTGCCA TGGACAGGGC TGTTTCTGAC GGGCCAGCCA TGATGCTAGC 250 TGCTGTGCTA CTTGTGAGGG CTACGGCGGC CAACATGTCC GGGACGTTTG 300 GAGGAGCCAA CGTGCCAAAC CTGTACCCGG GGGCCCCTGG GGGTGGTTAC 350 CCCCCAGTTC CCCCGGGGGG GTTCGGGCAG CCCCCTCCCG CCCAGCAGCC 400 TGTTCCTTCG TATGGAATGT ACCCGCCCCC TGGAGGAAAC CCCACCTCCG 450 GGATGCCTTC ATATCCGCCA TACCCAGGGG CCCCTGTGCC AGGCCAGCCC 500 ATGTTGCCCC CTGGACAGCA GCCCCCAGGG GTCTACCCTG GACAGCCGCC 550 CATGACCTAC CCTGGACAGT CACCAGTGCC ACCTCCTGGG CAGCAGCCAG 600 TGCCAAGCTA TCCAGGGTAC TCAGGTTCTG GGACTGTCAC CCCTGCCGTG 650 TCCCCCGCTC AGTTTGGAAA CCGAGGCACC ATCACAGATG CATCTGGCTT 700 TGACCCCCTG CGAGATGCTG AAGTCCTGCG GAAGGCCATG AAGGGCTTTG 750 GGACTGACGA GCAGGCCATC ATTGACTGCC TGGGTAGTCG CTCCAACAAG 800 CAACGACAGC AGATCCTCCT GTCGTTCAAG ACAGCATATG GGAAGGATTT 850 GATCAAAGAT CTGAAATCTG AACTGTCAGG AAACTTTGAG AAGACAATCT 900 TGGCCCTGAT GAAGACCCCT GTCCTCTTTG ACGCTTATGA GATAAAGGAA 950 GCTATCAAGG GGGCGGGCAC TGATGAAGCC TGCCTGATCG AGATCCTGGC 1000 CTCCCGCAGC AACGAGCACA TCCGGGAGCT GAACAGAGTC TACAAGACAG 1050 AATTCAAAAA GACCCTGGAG GAGGCCATTC GGAGCGACAC TTCAGGGCAC 2000 TTCCAGCGGC TCCTCATCTC TCTCTCTCAG GGAAACCGGG ATGAAAGCAC 2050 AAACGTGGAC ATGACCCTTG TCCAGAGAGA TGTGCAGGAG CTCTATGCAG 2150 CTGGGGAGAA CCGCCTGGGA ACAGATGAGT CCAAGTTCAA TGCGATTCTG 2200 TGCTCCCGGA GCCGGGCCCA CCTGGTGGCA GTTTTTAACG AGTATCAGAG 2250 GATGACAGGA CGTGACATTG AGAAGAGCAT CTGCCGGGAG ATGTCCGGGG 2300 ACCTGGAGCA GGGCATGCTG GCTGTGGTGA AATGTCTTAA GAATACCCCA 2350 GCCTTCTTTG CTGAAAGGCT CAACAAGGCC ATGAGGGGAG CCGGAACCAA 2400 AGACCGGACC CTGATCCGCA TCATGGTGTC TCGCAGCGAG ATCGACCTCC 2450 TGGACATCAG AGCAGAGTAT AAGCGGCTGT ATGGCAAGTC GCTGTACCAC 2500 GACATCACGG GAGACACTTC AGGGGATTAC CGGAAGATTC TGCTGAAGAT 2550 CTGTGGTGGC AATGACTGAG CAGTGGCTGG TGGGTCACTT CTGTCCACCT 2600 GCTGGCAACA GCAATGCCAG GAAAAGGCCA AAAGAACGTT TGTCTGTTTC 2650 TAACAAATCT ACAAAGTAGC CCCCAGGTGT CACAGTTCAG ACCAACTGTA 2700 (2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 505 (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Met Ser Tyr Pro Gly Tyr Pro Pro Pro Ala Gly Gly Tyr Pro Pro Gly 5 10 15 Ala Pro Gly Val Pro Glu Leu Glu Ser His Ala Gly Gly Pro Gin Gly 20 25 30 Leu Phe Ala Ala Met Asp Arg Ala Val Ser Asp Gly Pro Ala Met Met 35 40 45 Leu Ala Ala Val Leu Leu Val Arg Ala Thr Ala Ala Asn Met Ser Gly 50 55 60 Thr Phe Gly Gly Ala Asn Val Pro Asn Leu Tyr Pro Gly Ala Pro Gly 65 70 75 80 Gly Gly Tyr Pro Pro Val Pro Pro Gly Gly Phe Gly Gin Pro Pro Pro 85 90 95 Ala Gin Gin Pro Val Pro Ser Tyr Gly Met Tyr Pro Pro Pro Gly Gly 100 105 110 Asn Pro Thr Ser Gly Met Pro Ser Tyr Pro Pro Tyr Pro Gly Ala Pro 115 120 125 Val Pro Gly Gin Pro Met Leu Pro Pro Gly Gin Gin Pro Pro Gly Val 130 135 140 Tyr Pro Gly Gin Pro Pro Met Thr Tyr Pro Gly Gin Ser Pro Val Pro 145 150 155 160 Pro Pro Gly Gin Gin Pro Val Pro Ser Tyr Pro Gly Tyr Ser Gly Ser 165 170 175 Gly Thr Val Thr Pro Ala Val Ser Pro Ala Gin Phe Gly Asn Arg Gly 180 185 190 Thr He Thr Asp Ala Ser Gly Phe Asp Pro Leu Arg Asp Ala Glu Val 195 200 205 Leu Arg Lys Ala Met Lys Gly Phe Gly Thr Asp Glu Gin Ala He He 210 215 220 Asp Cys Leu Gly Ser Arg Ser Asn Lys Gin Arg Gin Gin He Leu Leu 225 230 235 240 Ser Phe Lys Thr Ala Tyr Gly Lys Asp Leu He Lys Asp Leu Lys Ser 245 250 255 Glu Leu Ser Gly Asn Phe Glu Lys Thr He Leu Ala Leu Met Lys Thr 260 265 270 Pro Val Leu Phe Asp Ala Tyr Glu He Lys Glu Ala He Lys Gly Ala 275 280 285 Gly Thr Asp Glu Ala Cys Leu He Glu He Leu Ala Ser Arg Ser Asn 290 295 300 Glu His He Arg Glu Leu Asn Arg Val Tyr Lys Thr Glu Phe Lys Lys 305 310 315 320 Thr Leu Glu Glu Ala He Arg Ser Asp Thr Ser Gly His Phe Gin Arg 325 330 335 Leu Leu He Ser Leu Ser Gin Gly Asn Arg Asp Glu Ser Thr Asn Val 340 345 350 Asp Met Thr Leu Val Gin Arg Asp Val Gin Glu Leu Tyr Ala Ala Gly 355 360 365 Glu Asn Arg Leu Gly Thr Asp Glu Ser Lys Phe Asn Ala He Leu Cys 370 375 380 Ser Arg Ser Arg Ala His Leu Val Ala Val Phe Asn Glu Tyr Gin Arg 385 390 395 400 Met Thr Gly Arg Asp He Glu Lys Ser He Cys Arg Glu Met Ser Gly 405 410 415 Asp Leu Glu Gin Gly Met Leu Ala Val Val Lys Cys Leu Lys Asn Thr 420 425 430 Pro Ala Phe Phe Ala Glu Arg Leu Asn Lys Ala Met Arg Gly Ala Gly 435 440 445 Thr Lys Asp Arg Thr Leu He Arg He Met Val Ser Arg Ser Glu He 450 455 460 Asp Leu Leu Asp He Arg Ala Glu Tyr Lys Arg Leu Tyr Gly Lys Ser 465 470 475 480 Leu Tyr His Asp He Thr Gly Asp Thr Ser Gly Asp Tyr Arg Lys He 485 490 495 Leu Leu Lys He Cys Gly Gly Asn Asp 500 505 (2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: AGATCTAGCC ATGAGCTCCC CAGGCTACC 29 (2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: CCCGCAGGTG GCTAGCCACC AGGT 24 (2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: AGGTTTGGCA CGTTGGATCC TCCAA 25 (2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: CAACTATGCA GGGCAGTTCA ACCA 24 (2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 9: CCACATTATC CAGCCCAATG GGAGGCA 27 (2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: AGCTGGAAAG CCACGCTGGA GGCC 24 (2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: TGGACAGGGC TGTTTCTGAC GGGCC 25 (2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: CAAGTAGCAC AGCAGCTAGC ATCATGGC 28

Claims: We claim: Claims 1. An isolated nucleic acid encoding an annexin XI polypeptide, said polypeptide having at least 70% homology to the amino acid sequence of bovine annexin XI type I (SEQ ID NO:2) or bovine annexin XI type II (SEQ ID NO:4) . 2. The nucleic acid of claim 1, said annexin XI polypeptide having at least 80% homology to the amino acid sequence of bovine annexin XI type I (SEQ ID NO:2) or bovine annexin XI type II (SEQ ID NO:4) . 3. The nucleic acid of claim 1, said annexin XI polypeptide having at least 90% homology to the amino acid sequence of bovine annexin XI type I (SEQ ID NO:2 or bovine annexin XI type II (SEQ ID NO:4). 4. The nucleic acid of claim 1, said nucleic acid sequence having at least 70% homology to bovine annexin XI type I cDNA (SEQ ID N0:1) or bovine annexin XI type II CDNA (SEQ ID NO:3) . 5. The nucleic acid of claim 1, said nucleic acid encoding a human annexin XI polypeptide. 6. A plasmid comprising the nucleic acid of claim 1. 7. The plasmid of claim 6, said plasmid further comprising an expression control sequence capable of directing expression of said annexin XI polypeptide. 8. A cell comprising the nucleic acid of claim 1. 9. The cell of claim 7 wherein said cell is a prokaryotic cell. 10. The cell of claim 8 wherein said cell is a eukaryotic cell. 11. The cell of claim 10 wherein said cell is mammalian cell. 12. Annexin XI produced by expression of the nucleic acid of claim 1. 13. Annexin XI produced by the cell of claim 8. 14. An antibody generated against all or an immunogenic portion of annexin XI, which antibody is capable of specifically forming an immune complex with annexin XI. 15. A substantially pure annexin XI polypeptide. 16. The annexin XI polypeptide of claim 15, said annexin XI polypeptide having at least 70% homology to the amino acid sequence of bovine annexin XI type I (SEQ ID NO: 2 or bovine annexin type II (SEQ ID NO:4). 17. The annexin XI polypeptide of claim 16, said annexin XI polypeptide having at least 80% homology to the amino acid sequence of bovine annexin XI type I (SEQ ID NO: 2) or bovine annexin type II (SEQ ID NO:4). 18. The annexin XI polypeptide of claim 17, said annexin XI polypeptide having at least 90% homology to the amino acid sequence of bovine annexin XI type I (SEQ ID NO: 2) or bovine annexin type II (SEQ ID NO:4). 19. The polypeptide of claim 15, said polypeptide being a human annexin XI polypeptide. 20. The polypeptide of claim 15 having the sequence of SEQ ID NO: 2 or SEQ ID NO:4. 21. A therapeutic composition comprising, in a pharmaceutically-acceptable carrier, the polypeptide of claim 15, or a coagulation inhibiting-fragment thereof. 22. A therapeutic composition comprising, in a pharmaceutically-acceptable carrier, the polypeptide of claim 15, or an anti-inflammatory fragment thereof. 23. A therapeutic composition comprising, in a pharmaceutically-acceptable carrier, the polypeptide of claim 15, or a phospholipase A 2 -inhibiting fragment thereof. 24. A method of detecting annexin XI in a sample of biological fluid, comprising: (a) contacting said sample of biological fluid with the antibody of claim 14; and (b) detecting immune complexes formed in step (a) , formation of said immune complexes being an indication of the presence of said annexin XI. 25. A method of detecting an antibody reactive with annexin XI in a sample of biological fluid, comprising: (a) contacting said sample of biological fluid with the annexin XI polypeptide of claim 15 or an immunogenic fragment thereof; and (b) detecting immune complexes formed in step (a) , formation of said immune complexes being an indication of the presence of said antibody reactive with annexin XI.

Inventors: TOWLE CHRISTINE A, TREADWELL BENJAMIN V, TOWLE, CHRISTINE, A., TREADWELL, BENJAMIN, V.
Applicants: GEN HOSPITAL CORP, THE GENERAL HOSPITAL CORPORATION
Application year: 1992
Main classification: C07K13
IPC codes: A61K38, C07K14, C12N1, C12N15